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Abstract  26 
 27 
CT chest scanning has been recommended to screen for pleuropulmonary blastoma 28 
(PPB) in babies and young children known to harbor germline DICER1 mutations. 29 
However, only a minority of these patients will develop PPB, and the use of CT scans 30 
is associated with risks such as secondary malignancy. Recently, we identified a panel 31 
of microRNAs that were highly abundant in the serum of a patient with a germline 32 
DICER1-mutated PPB, but present at normal levels in healthy relatives carrying the 33 
same germline mutation. Consequently, we advocate the addition of serum 34 
microRNA profiling to this programme of radiological surveillance, in order to 35 
establish its clinical utility as a PPB biomarker. If validated, this blood-based 36 
screening-tool may reduce our reliance on CT imaging.  37 
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Letter to the Editor 38 
 39 
We read with interest the article ‘Judicious DICER1 Testing and Surveillance Imaging 40 
Facilitates Early Diagnosis and Cure of Pleuropulmonary Blastoma’ [1], as it raised 41 
pertinent issues for the management of families known to carry DICER1 mutations. 42 
The authors suggest that to detect early-stage (i.e. Type I) pleuropulmonary blastoma 43 
(PPB), for which survival rates are >90% [2], children known to harbor a germline 44 
DICER1 mutation should receive CT chest scan at 3 months of age, and again at 1-2 45 
years if the first scan is negative [1]. 46 
 47 
Although the majority of PPB patients are found to have germline DICER1 mutations, 48 
penetrance is low. The majority of mutation carriers are unaffected [3], with only 10-49 
20% estimated to develop PPB. Consequently, any screening programmes for PPB in 50 
patients with germline DICER1 mutations needs to be as non-invasive as possible, 51 
minimizing exposure to ionizing radiation. Serum microRNA profiling may be an 52 
important addition to any programme of radiological surveillance. 53 
 54 
Serum microRNAs show considerable promise as cancer biomarkers [4], particularly 55 
as they are highly stable and resistant to degradation [5]. We recently identified a 56 
panel of microRNAs that were more abundant in the serum of a 2-year-old female at 57 
the time-of-diagnosis of an advanced (Type III) PPB, compared with patients with 58 
other solid tumors of childhood and a non-malignant control group [6]. The patient 59 
carried a germline DICER1 mutation and the PPB cells showed a further somatic 60 
‘hotspot’ mutation in the DICER1 RNaseIIIb domain, consistent with other reports [7]. 61 
Amongst the over-expressed serum microRNAs, there was significant over-62 
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representation of -3p strands, in keeping with the observation that DICER1 RNaseIIIb 63 
hotspot mutations result in a -3p strand bias in affected tissues [8]. Two specific 64 
microRNAs from this panel (miR-125a-3p/miR-125b-2-3p), had highly elevated 65 
serum levels at PPB diagnosis and demonstrated early treatment-related reductions [6]. 66 
Importantly, in healthy family members with germline DICER1 mutations, serum 67 
levels of these two microRNAs were similar to the control group, suggesting that the 68 
changes in the patient were directly attributable to release of microRNAs from the 69 
PPB tumor cells into the bloodstream and not from the germline DICER1 mutation per 70 
se. 71 
 72 
Comprehensive evaluation of the clinical utility of serum microRNAs is now 73 
warranted in two patient groups. First, as a longitudinal screening-tool in patients with 74 
germline DICER1 mutations, initially in parallel with judicious radiological imaging, 75 
to identify whether levels of PPB-specific serum microRNAs [6] are elevated in early-76 
stage disease, where outcomes are more favorable [2]. Second, in patients presenting 77 
de novo with a lung lesion, in order to resolve diagnostic dilemmas, e.g. distinguishing 78 
PPB from developmental anomalies such as congenital cystic adenomatous 79 
malformation (CCAM) [9]. As CCAMs are not associated with germline and somatic 80 
DICER1 mutations, we hypothesize that the serum profiles obtained would not show 81 
the PPB-associated -3p strand bias. 82 
 83 
In summary, if the utility of longitudinal serum microRNA monitoring is confirmed in 84 
a larger cohort of patients with germline DICER1 mutations, the resultant decrease in 85 
CT scans will reduce the associated radiation-risk to babies and very young children 86 
[10].  87 
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